Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viskase Holdings, Inc. (ENZN) filings document the issuer's completed transition from Enzon Pharmaceuticals, Inc. to Viskase Holdings, including material-event reports on the merger closing, name change, exchange offer for Series C Non-Convertible Redeemable Preferred Stock, and related capital-structure disclosures.
The company's 8-K records also cover governance and ownership matters, including a Section 382 Rights Agreement, changes in certifying accountant, officer appointments, and amendments to the credit agreement of Viskase Companies, LLC, a wholly owned subsidiary. Other recurring disclosure areas include shareholder voting matters, material agreements, operating and financial results, risk factors, and legacy clinical or regulatory disclosures.
Enzon Pharmaceuticals, Inc. issued a press release announcing the completion of the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock on March 25, 2026. The press release is attached as Exhibit 99.1 and incorporated by reference; the exhibit is not being "filed" for purposes of Section 18 of the Exchange Act.
Enzon Pharmaceuticals, Inc. reported that it has completed the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock. The company disclosed this by issuing a press release, which is included as an exhibit to the report and incorporated by reference.
The information and attached press release are being furnished rather than filed, meaning they are not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities law filings unless specifically referenced.
Enzon Pharmaceuticals, Inc. reports the final results of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock. The offer expired at 5:00 p.m., Eastern Time, on March 24, 2026. The depositary reported 339 shares were validly tendered and not withdrawn, representing less than 1% of the 40,000 Series C shares outstanding as of March 24, 2026. Enzon accepted for exchange all validly tendered shares and will exchange them in accordance with the offer terms. A press release dated March 25, 2026 announcing results is attached as an exhibit.
Enzon Pharmaceuticals, Inc. amends its Schedule TO to report developments in the exchange offer to convert Series C Non-Convertible Redeemable Preferred Stock into shares of Common Stock. The amendment states the Reverse Stock Split became effective on March 24, 2026 at 4:30 p.m. Eastern Time and that Common Stock is expected to trade on a reverse-split adjusted basis on the OTCQB at market open on March 25, 2026. The company states the Reverse Stock Split was required prior to the consummation of the Merger. All other Offer terms and disclosures are incorporated by reference to the Prospectus/Consent Solicitation/Offer to Exchange.
Enzon Pharmaceuticals amended its Section 382 Rights Agreement and implemented a 1-for-100 reverse stock split. The Eleventh Amendment moves the Final Expiration Date of the Rights Agreement to noon, New York City time, on March 26, 2026. The Reverse Stock Split became effective at 4:30 p.m. ET on March 24, 2026, and Enzon’s common stock is expected to trade on an adjusted basis on the OTCQB at market open on March 25, 2026, under the temporary symbol ENZND for 20 trading days. No fractional shares will be issued; holders entitled to fractions will receive cash payments. The Reverse Stock Split must be completed prior to the contemplated merger with Viskase Companies, Inc.
Enzon Pharmaceuticals, Inc. approved an Eleventh Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date to noon, New York City time, on March 26, 2026, with no other changes to the agreement.
The company also implemented a previously approved 1-for-100 reverse stock split, effective at 4:30 p.m. Eastern on March 24, 2026. Every 100 shares of common stock are being combined into 1 share, with the par value unchanged and fractional holdings settled in cash. Enzon’s common stock is expected to begin trading on a split-adjusted basis on the OTCQB on March 25, 2026 under the temporary symbol “ENZND” for 20 trading days. The reverse split was completed to make authorized shares available for the anticipated merger with Viskase Companies, Inc. and related common stock issuances in an outstanding exchange offer.
Enzon Pharmaceuticals announced an extension of its exchange offer for holders of Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. The Offer now expires at 5:00 p.m. Eastern on March 24, 2026, unless further extended.
The filing also reiterates that Enzon and Viskase Companies, Inc. have a proposed merger and that a Form S-4 registration statement containing a prospectus, consent solicitation statement and offer to exchange has been filed and is available on www.sec.gov and Enzon’s website.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer for shares of its Series C Non-Convertible Redeemable Preferred Stock to 5:00 p.m. Eastern time on March 24, 2026. The offer lets holders swap preferred shares for Enzon common stock.
The exchange offer is part of a broader set of proposed transactions between Enzon and Viskase Companies, Inc., which are described in a previously filed Form S-4 registration statement containing a prospectus, consent solicitation statement and offer to exchange for the combined company.
Enzon Pharmaceuticals amended its Schedule TO to announce an extension of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock. The offer now expires at 5:00 p.m., Eastern Time, on March 24, 2026. The exchange ratio is the aggregate liquidation preference per share divided by $7.83 after giving effect to the Reverse Stock Split.
As of 5:00 p.m., Eastern Time, on March 18, 2026, a total of 339 shares had been validly tendered and not withdrawn, representing <1% of the 40,000 shares outstanding as of March 18, 2026. Holders who already tendered need not re-tender; all procedural documents are incorporated by reference.
Enzon Pharmaceuticals, Inc. entered into the Tenth Amendment to its Section 382 Rights Agreement to extend the Final Expiration Date of the rights from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026.
Except for this adjustment to the Final Expiration Date, the Rights Agreement remains unmodified.